@kcferdmd Thanks for the clear presentation and yes a lot more to do. Sorry we did not get to chat this meeting. Hopefully will see you at another venue soon.
@Lpa_Doc Sam thanks for putting this out there. We can all hypothesize but it is best to wait and see the data. It does not help the field to provide opinions based on assumptions. Let the data drive any opinions. Don’t start worrying before the message is revealed.
@dramitkhera@ASPCardio@DrMarthaGulati She looks so good! She is a rockstar! I was always impressed by her productivity during my training at cuimc! Her trainees have done really well here.
1. seeing all the results will be extremely educational for the field.
2. Congrats to researchers, patients and the village that made this first study of this class of therapies a success (yes I said succees).
3. Science is never easy.
Novartis announces Lp(a)HORIZON Phase III topline results
“did not meet its primary endpoint”
There will be a lot to unpack here https://t.co/UBfd8miBXC
@sciqst@Lpa_Doc@Lpa_Doc I have found that the exclusion/inclusion criteria of these studies are different-slightly different. We have done similar analysis of the data and also see differences than what is published. The levels of lpa (higher ones) are not included in all the published studies
@drpablocorral@drpablocorral there was a variant in the lpa kv2 region that was associated to glucose levels. The paper should be published this week. May not explain the full epi findings but maybe relevant in some individuals.
🚨 AHA/ATVB Members:
ATVB Membership Committee will be hosting a Town Hall with @KateyRayner, incoming Chair of the @ATVBCouncil
Hear her vision for the @AHAScience community ATVB & let her know what matters most to you!
📅 April 2 | 5 PM ET
Register:
https://t.co/LP4aIDRdWT
Publication of Collaborative project: Take home: Lp(a) is associated with Athero-Stroke, mainly ECAD. Its a start, larger cohorts are needed. https://t.co/WsqXeRI97M